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choice instrument to elicit women’s tradeoff preferences for
various treatment attributes, including both beneﬁts and risks 
for therapies to relieve vasomotor symptoms. The survey was
administered to 500 US women between the ages of 46 and 60,
randomly sampled from a large internet consumer panel. Two
survey versions were administered to split samples. The versions
were identical except that risk descriptions incorporated relative
risks in one version and absolute risks in the other version.
Ordered-probit importance weights for various health states and
risks were estimated from the resulting tradeoff data. RESULTS:
We found that the risk description did not affect ordered-probit
estimates of respondents’ preferences for risk of fracture and
heart attack, but did affect preferences for the risk of breast
cancer. Subjects who received the relative-risk versions indicated
that a decrease in risk of breast cancer from 3.9% to 2.3% was
64% more important than subjects who received the absolute-
risk version. Conversely, subjects who received the absolute-risk
version were more concerned about relieving vasomotor symp-
toms. Relieving the severity of hot ﬂashes was 44% more impor-
tant, reducing the frequency of hot ﬂashes was 40% more
important, and reducing the frequency of night sweats was 50%
more important for subjects who received the absolute-risk
version than for subjects who received the relative risk version.
CONCLUSION: Although health professionals presumably
interpret clinical relative-risk results in the context of the base
prevalence of a condition, laypersons often do not have access
to base-rate information. Our results suggest that more careful
characterization of adverse-event risks is important in helping
women make fully informed choices among alternative treat-
ments for vasomotor symptoms.
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OBJECTIVES: EQ-5D is one of the most widely used index mea-
sures of health-related quality of life. Ten years have passed since
the ﬁrst UK national survey that established preference weights
for EQ-5D health states. That protocol elicited values for 45 of
the 245 possible EQ-5D health states. Values for the remaining
health states were interpolated from estimation models based on
the values for directly observed states. The process of model con-
struction and testing was onerous and labour intensive. Esti-
mated values remained largely untested as replication studies are
virtually non-existent. This paper reports on an alternative
approach in which values for ALL health states are elicited.
METHODS: The standard questionnaire used to value EQ-5D
health states records VAS ratings on a 0–100 scale, for 16 health
states presented as two groups of eight on consecutive pages. 
The logically best and worst health states are repeated on each
page. A value for dead is also elicited in each questionnaire. 
For this study, 21 versions of the questionnaire were designed,
each presenting 14 different states. Questionnaires were mailed
to 1100 individuals selected randomly from the electoral regis-
ters of England and Wales. RESULTS: A response rate of 62%
was achieved (n = 685). Mean VAS scores from this survey 
were similar to those elicited ten years earlier although the 
value for dead was 45% higher than its predecessor. A smooth,
well-behaved set of values for all 245 states was derived using
OLS regression (r2 = 0.974, p < 0.001). Transformed to a 0–1
scale, values were systematically higher than the corresponding
TTO weights used as standard in NICE appraisals reporting EQ-
5D. Only 12 states demonstrate negative values. CONCLU-
SIONS: Traditional interview-based procedures are costly. This
study demonstrates the feasibility of postal survey methods and
simultaneously poses a dilemma for end-users. Are contempo-
rary VAS–based values preferable to decade old TTO-based
values?
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OBJECTIVES: The FDA currently requires patient interviews in
the process of developing a new PRO measure. In the past, many
questionnaires were developed based solely on clinician exper-
tise and patient involvement in the creation of items was non-
existent. In order to ensure existing questionnaires are accepted
by the FDA, it is necessary to conﬁrm the content validity of
